tiprankstipranks
Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks
The Fly

Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks

Cantor Fitzgerald analyst Louise Chen argues that the idiosyncratic risk/reward displayed in pharma, biopharma and biotech in 2022 is likely to persist through the first half of 2023. In this context, she "would be owning" Merck (MRK), calling it her top pick in large cap pharma. Among the small-to-mid caps in the space, Chen identifies Aclaris Therapeutics (ACRS), Arcutis Biotherapeutics (ARQT), EyePoint (EYPT), Vaxcyte (PCVX), Precigen (PGEN), ProQR Therapeutics (PRQR), Poseida Therapeutics (PSTX) and Roivant Sciences (ROIV) as top picks. Chen also highlights Fortress Biotech (FBIO) for its "risk-diversified partner-based business model." The analyst has Overweight ratings on all the stocks mentioned.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MRK:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles